Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment for locally advanced breast cancer.
Breast Neoplasms
DRUG: Zometa|DRUG: Epirubicin|DRUG: Docetaxel|DRUG: Trastuzumab|RADIATION: External beam radiation|PROCEDURE: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Evaluate the impact of Zometa (zoledronic acid) on the clearance of bone marrow micrometastases, Prior to therapy initiation, after completion of neoadjuvant chemotherapy, and 12-15 months from registration|Evaluate the protective effect of Zometa (zoledronic acid) on chemotherapy-induced loss of bone mineral density, Prior to therapy initiation and 12-15 months from registration
Impact of Zometa (zoledronic acid) on time and site of relapse, 5 years from registration|Effect of treatment on quality of life in women undergoing treatment for LABC., Baseline and 12-15 months from registration
This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment for locally advanced breast cancer.